Given the prediction from human genetic association studies that blockade of IL‐6 classic signalling could have an opposing effect on asthma symptoms when compared to blockade of trans‐signalling (aggravate and attenuate, respectively), it is not clear what effect should be expected from drugs that block both pathways, such as tocilizumab or sarilumab. The gene discussed is IL6; the disease is asthma.